Blue Water Vaccines Announces Closing of Initial Public Offering
Blue Water Vaccines Inc. (BWV) successfully completed its initial public offering (IPO) on February 23, 2022, raising approximately $20 million from selling 2,222,222 shares at a price of $9.00 per share. The shares began trading on the Nasdaq under the ticker symbol BWV on February 18, 2022. Boustead Securities, LLC was the sole book-running manager for the offering. The IPO aims to support the company's development of innovative vaccines addressing significant health challenges globally, including a universal flu vaccine and a candidate for pneumococcus.
- Raised approximately $20 million from IPO to fund vaccine development.
- Plans to enhance vaccine offerings with a universal flu vaccine and a pneumococcus vaccine targeting middle ear infections in children.
- None.
Insights
Analyzing...
CINCINNATI, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing vaccines, today announced the closing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of
The aggregate gross proceeds to BWV from the initial public offering were approximately
Boustead Securities, LLC acted as the sole book-running manager for the offering.
The Securities and Exchange Commission (“SEC”) declared effective a registration statement on Form S-1 relating to these securities on February 11, 2022. A final prospectus relating to this offering was filed with the Securities and Exchange Commission on February 22, 2022. The offering was made only by means of a prospectus, copies of which may be obtained from; Boustead Securities, LLC, Attention: Prospectus Department, 6 Venture, Suite 325, Irvine, CA 92618, or by telephone at 949-502-4408 or by email at offerings@boustead1828.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Bluewater Vaccines
Blue Water Vaccines, Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains and a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. Additionally, Blue Water Vaccines has licensed a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria among others. For more information, visit www.bluewatervaccines.com.
FAQ
What was the share price for BWV's IPO?
How much capital did BWV raise from its initial public offering?
When did BWV's shares begin trading on the Nasdaq?
Who managed the initial public offering for BWV?
What are the main vaccine projects Blue Water Vaccines is working on?
